Mubadala Capital, the asset management subsidiary of Abu Dhabi’s sovereign wealth fund, has participated in a new $30 million funding round for Tahoe Therapeutics, a US-based company specializing in the development of virtual models of human cells.
By the Numbers
- $30 Million: The total value of the new funding round.
- 1 Billion: The number of single-cell data points the company plans to generate.
A Strategic Investment in the Future of Medicine
This investment from Mubadala Capital highlights a strategic focus on backing cutting-edge, deep-tech companies that are poised to revolutionize the healthcare industry. By supporting Tahoe Therapeutics, the Abu Dhabi-based firm is investing in a platform that uses artificial intelligence to create the largest-ever database for training AI models in human cell behavior. This technology aims to develop highly precise drugs for cancer and other diseases and to reduce the failure rate of clinical trials.
Investing Alongside Top-Tier Global VCs
The funding round was led by Amplify Partners and saw Mubadala Capital investing alongside a prominent syndicate of global venture capital firms, including Databricks Ventures, Wing Venture Capital, and General Catalyst. This places the Abu Dhabi investor at the heart of a major international deal in the competitive biotech space.
About the Partners
- Mubadala Capital: The global asset management arm of Mubadala Investment Company, Abu Dhabi’s sovereign investor. It manages a diverse portfolio of assets and investments, including a significant venture capital practice.
- Tahoe Therapeutics: A US-based biotechnology company that is building a platform to create virtual models of human cells to accelerate the development of new, more precise medicines.
Looking Ahead
With this new funding, Tahoe Therapeutics plans to expand its therapeutic programs and select a single strategic partner from the pharmaceutical or AI industries to access its next-generation database. For Mubadala Capital, this investment adds a pioneering biotech company to its portfolio and reinforces Abu Dhabi’s role as a key source of strategic capital for global innovation.
Source: Jawlah